Yechun Pang

机构：Shanghai Medical College of Fudan University, Fudan University, Fudan University Shanghai Cancer Center, Shanghai Institute of Hematology, Shanghai Clinical Research Center

发表论文 17 篇 · 总被引 149 次 · h-index 7

代表论文

• Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial (2024 · EClinicalMedicine · 被引 26)
• MiR-103a promotes tumour growth and influences glucose metabolism in hepatocellular carcinoma (2021 · Cell Death and Disease · 被引 23)
• MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer (2022 · Cell Death and Disease · 被引 22)
• Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial (2024 · Nature Communications · 被引 19)
• Identification of a novel subtype of SPP1 + macrophages expressing SIRPα: implications for tumor immune evasion and treatment response prediction (2024 · Experimental Hematology and Oncology · 被引 14)
• Engineered multitargeting exosomes carrying miR-323a-3p for CRC therapy (2023 · International Journal of Biological Macromolecules · 被引 13)